GeoVax Labs Inc. (GOVX) shares soared 63.26% in after-hours on Thursday, August 19, 2021, and closed the daily trading at $7.02. Earlier in the regular trading session on Thursday, GOVX’s stock gained 6.70%. GOVX shares have fallen 60.69% over the last 12 months, and they have moved up 5.39% in the past week. Over the past three months, the stock has lost 20.37%, while over the past six months, it has shed 36.76%. The company has a current market of $27.52 million and its outstanding shares stood at 6.32 million.

GOVX Covid-19 vaccine data presentation

On August 19, 2021, GeoVax Labs, Inc. (GOVX) presented data from ongoing studies of its preventive vaccine against COVID-19. The presentation titled, “Design of a Universal SARS-CoV-2 Vaccine Against Evolving Variants,” was delivered virtually by Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer, during the European Society of Medicine (ESMED) General Assembly, being held August 19-21 in Berlin, Germany.

GOVX participation in the recent investor conference

GeoVax Labs, Inc. (GOVX), recently participated at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18, 2021, at 12:30 PM EST. David Dodd, Chairman, and CEO presented the company and answered questions from investors.

The company also participated at the Alliance Global Partners Virtual Healthcare Symposium which was held on Thursday, June 17, 2021, and at BIO Digital which was held from June 10- to June 18, 2021.

GOVX recent financial results announcement

On August 11, 2021, GeoVax Labs, Inc. (GOVX), reported its financial results for the quarter ended June 30, 2021.

Q2 2021 financial highlights

• Total Grant and collaboration revenue was $79,708 in Q2 2021 compared to $440,602 for Q2 2020.
• Total operating expenses were $1,566,000 in Q2 2021 compared to $ 889,000 in Q2 2020.
• GOVX suffered a net loss of $1.3 million in Q2 2021 compared to $455,000 in Q2 2020.
• Loss per common share was $0.21 in Q2 2021 compared to $0.66 in Q2 2020.
• As of June 30, 2021, GeoVax had cash balances of $19.5 million compared to $9.9 million on December 31, 2020.

Hepatitis B Vaccine Patent

On July 07, 2021, GeoVax Labs, Inc.  announced that the U.S. Patent and Trademark Office has issued Patent No. 11,052,148, entitled “Composition and Methods of Generating an Immune Response to Hepatitis B Virus.”

The work supporting the patent application was performed through a collaboration between GeoVax and Georgia State University and the patent is jointly owned by the Company and the Georgia State University Research Foundation.

Conclusion

GOVX stock surged after the company announced its Covid 19 vaccination data and it can continue its surge on Friday as well.